Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
VTCN1 Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | Q7Z7D3 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 30878 Da |
| Antigen Region | 72-100 aa |
| Gene ID | 79679 |
|---|---|
| Other Names | V-set domain-containing T-cell activation inhibitor 1, B7 homolog 4, B7-H4, B7h5, Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, VTCN1 {ECO:0000312|EMBL:EAW566721} |
| Target/Specificity | This VTCN1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 72-100 amino acids from the Central region of human VTCN1. |
| Dilution | WB~~1:1000 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | VTCN1 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | VTCN1 {ECO:0000312|EMBL:EAW56672.1} |
|---|---|
| Function | Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T- cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation. |
| Cellular Location | Cell membrane; Single-pass type I membrane protein. Note=Expressed at the cell surface. A soluble form has also been detected. {ECO:0000255, ECO:0000269|PubMed:12818165, ECO:0000269|PubMed:15878339, ECO:0000269|PubMed:16782226} |
| Tissue Location | Overexpressed in breast, ovarian, endometrial, renal cell (RCC) and non-small-cell lung cancers (NSCLC). Expressed on activated T- and B-cells, monocytes and dendritic cells, but not expressed in most normal tissues (at protein level). Widely expressed, including in kidney, liver, lung, ovary, placenta, spleen and testis |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
VTCN1 belongs to the B7 family (see CD80; MIM 112203) of costimulatory proteins. These proteins are expressed on the surface of antigen-presenting cells and interact with ligands (e.g., CD28; MIM 186760) on T lymphocytes.
References
Xue, Q., et al. Stem Cells Dev. 19(1):27-38(2010)
Cheng, L., et al. Int. J. Gynecol. Cancer 19(9):1481-1486(2009)
Hinks, A., et al. Arthritis Rheum. 60(1):258-263(2009)
Zhang, J., et al. BMC Cancer 9, 394 (2009) :
Thompson, R.H., et al. Cancer Res. 68(15):6054-6058(2008)
Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003)
Zang, X., et al. Proc. Natl. Acad. Sci. U.S.A. 100(18):10388-10392(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
